Linda A. Kroger

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

Gerald L. DeNardo, Sally J. DeNardo, D S Goldstein et al. · Journal of Clinical Oncology · 1998 · 182 citations

Medicine, Nuclear Medicine, Oncology +17

Osteitis Caused by Bacille Calmette-Guerin Vaccination: A Retrospective Analysis of 222 Cases

Linda A. Kroger, Matti Korppi, E Brander et al. · The Journal of Infectious Diseases · 1995 · 122 citations

Medicine, Infectious Diseases, Pediatrics +13

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts

Sally J. DeNardo, David L. Kukis, Linda A. Kroger et al. · Proceedings of the National Academy of Sciences · 1997 · 109 citations

Medicine, Oncology, Pharmacology +17

Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using ¹³¹ I-LYM-1 Antibody

Gerald L. DeNardo, Sally J. DeNardo, Kathleen R. Lamborn et al. · Cancer Biotherapy and Radiopharmaceuticals · 1998 · 95 citations

Medicine, Nuclear Medicine, Oncology +13

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

Sally J. DeNardo, Gerald L. DeNardo, David L. Kukis et al. · PubMed · 1999 · 65 citations

Medicine, Oncology, Pharmacokinetics +17